ArticleEClinicalMedicine2024

Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study.

Thierry Passeron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.